ArticleJournal, genetic engineering & biotechnology2025
The effects of gut microbiota-derived short-chain fatty acids (SCFAs) on human colon cancer cells: An in vitro study.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) has always been a major concern for researchers due to its deadly nature. One of the microbial metabolites found in the gut is short-chain fatty acids (SCFAs), which have the ability to regulate the immune system and exert protective effects against CRC. In this study, we investigated the effects of SCFAs on the expression of the CYP1A1 gene in Caco-2 cells at varying concentrations. The Caco-2 cell line and HDF control cell line were treated with three concentrations (7.5, 15, and 30 mM) of NaA(sodium acetate), NaB(sodium butyrate), and NaP(sodium propionate) for three different time periods (24, 48, and 72 h). Additionally, two concentrations (2.5 and 10 μM) of CH223191 (an AhR gene antagonist) alone and a concentration of 10 μM of CH223191 in combination with the mentioned concentrations of NaA, NaB and NaP were applied to the cells for 48 h. The gene expression of CYP1A1 was examined using Real-time PCR. The expression of the CYP1A1 gene increased with concentrations of NaA and NaB at all time points, and with 30 mM of NaP at 24 h (p < 0.05). However, increasing the concentration of NaB and NaP led to decreased expression of the CYP1A1 gene. These findings suggest the potential use of SCFAs as epigenetic drugs for the prevention and treatment of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.